In these experiments, CAR-T cells targeting lymphoma (CD19 CAR-T cells), lymphoma overexpressing PD-L1 (PD-L1 CAR-T cells) and breast cancer (HER-2 CAR-T cells) were cultured with cancer cells expressing the corresponding antigens in the presence of RSL3. This evidence concerns the gene CD19 and lymphoma.